All posts by: Michael Zand

About Michael Zand

Scientists announce breakthrough in stem cell research – UPI.com

Continue reading

2017-04-07 NEWS

UPI.com

Scientists announce breakthrough in stem cell research
UPI.com
April 6 (UPI) — Scientists have already successfully developed pluripotent stem cells in the lab, cells which can form any type of tissue. Totipotent stem cells are the pinnacle for stem cell scientists, however. And for the first time, researchers
First Clinic-Ready Stem Cell RepositoryThe Scientist
NHLBI stem cell consortium provides new insights into genetics of heart disease, other conditionsNational Institutes of Health (press release)
Can Stem Cell ‘Patch’ Help Heart Failure?Everyday Health (blog)
Phys.Org –Engadget –Medical Xpress
all 69 news articles »
Continue reading

2017-04-07 NEWS

Street Register

After Recent Developments Trading in US Stem Cell Inc (OTCMKTS:USRM) Increased Momentum
Street Register
US Stem Cell Inc (OTCMKTS:USRM) shares have been up significantly recently, and the rise could continue. The stock was up over 300% in a one month period recently, However, it looks like that recent meteoric rise could continue. If you’ve been

and more »

Continue reading

2017-04-07 NEWS

CBS New York

Stem Cell Treatment Might Reverse Symptoms Of Multiple Sclerosis …
CBS New York
There’s potentially exciting news for the two and a half million people around the world struggling with multiple sclerosis.

and more »

Continue reading

2017-04-06 NEWS

Future of Immunotherapy Use in Lung Cancer
OncLive
Benjamin P. Levy, MD: We’ve come quite a ways, in the past few years, with single agent immunotherapy. And now, the next horizon, and the next frontier, is what I call I-O (immuno-oncology), or “immunotherapy combination mania,” or “combo mania.”

Continue reading

2017-04-06 NEWS

Madison.com

The First CART Drugs Have Left the Gate
Madison.com
CAR-T treatments take T cells out of a patient, genetically modify the cells so they’re programmed to attack tumor cells expressing a specific protein, and then infuse them back into the patients to attack the cancerous cells. Both Novartis’ and Kite

and more »